Document is current
Any future updates will be listed below
-
Authors
Di Carlo, Dino https://orcid.org/0000-0003-3942-4284
Morsut, Leonardo
McCain, Megan L. https://orcid.org/0000-0003-1908-6783
Wright, Heather J.
Abedi, Mohamad
Yamada-Hunter, Sean A. https://orcid.org/0000-0002-4372-6587
Zhang, Jason Z. https://orcid.org/0000-0003-0091-6273
Backus, Keriann https://orcid.org/0000-0001-8541-1404
Chung, Eunji
Wang, Yingxiao https://orcid.org/0000-0003-0265-326X
Rando, Thomas A.
Cai, Long https://orcid.org/0000-0002-7154-5361
Thomson, Matt https://orcid.org/0000-0003-1021-1234
Elowitz, Michael B. https://orcid.org/0000-0002-1221-0967
Lee, John K.
Witte, Owen https://orcid.org/0000-0003-4461-4533
-
Funding
Funding for this research was provided by:
Silicon Valley Community Foundation (2023-332386)
Silicon Valley Community Foundation (2023-332386)
Silicon Valley Community Foundation (2023-332386)
- License Information
-
More Information
Article History
Received: 3 December 2025
Accepted: 18 May 2026
First Online: 23 June 2026
Competing interests
: D.D.C. and the Regents of the University of California have financial interests in Partillion Bioscience, Forcyte Biotechnologies and Saku Biosciences, which commercialize technologies that could be applied to the Billion Cell×Cell Project. O.W. currently has consulting, equity and/or board relationships with Trethera Corporation, Breakthrough Properties, Vida Ventures, Nammi Therapeutics, Two River, Iconovir, Appia BioSciences, Neogene Therapeutics, 76Bio and Allogene Therapeutics. None of these companies contributed to or directed any of the research reported in this article. J.K.L. holds equity in and serves as the Chief Medical Officer of PromiCell. J.K.L. also serves as a consultant for Lyell Immunpharma and Xilio Therapeutics. E.C. serves as Chief Scientific Officer for Silver Spur Therapeutics. M.E. is a cofounder, scientific advisory board member or consultant at TeraCyte, Plasmidsaurus, Asymptote Genetic Medicines and Spatial Genomics. All other authors declare no competing interests.
